Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature Reviews. Nephrology|April 23, 2009
ANCA-associated vasculitis: from bench research to novel treatmentsLalit Pallan, Caroline O Savage, Lorraine Harper
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 24, 2022
Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case seriesAlice Tew, Leila Khoja, Lalit Pallan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 22, 2023
CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world datasetWilliam Buller, Lalit Pallan, Teresa Chu, et al.
Case Reports in Oncological Medicine|May 10, 2022
Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma PatientP Kissoonsingh, B Sutton, Syed U Iqbal, et al.
Clinical Medicine (London, England)|August 7, 2025
Immune checkpoint inhibitor-induced inflammatory arthritisBenjamin A Fisher, Andrew Allard, Shirish Dubey, et al.
European Journal of Immunology|September 21, 2011
Early B blasts acquire a capacity for Ig class switch recombination that is lost as they become plasmablastsJennifer L Marshall, Yang Zhang, Lalit Pallan, et al.
Immunotherapy Advances|May 12, 2025
Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activationLozan Sheriff, Alastair Copland, David A J Lecky, et al.
Blood|September 21, 2007
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemiaEduardo Olavarria, Shamyla Siddique, Michael J Griffiths, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Pageof 2